RIPK1 and neoplasm: Using a Brca1<sup>−/−</sup>p53<sup>−/−</sup> organoid-derived TNBC model that recapitulates the immune landscapes of basal-like tumours, we show that RIPK1-driven ICD synergises with anti-PD-1 therapy to induce durable tumour control and immune memory in immune-infiltrated tumours.